Clinical Trial Update: COVID Protection After Transplant-Immunosuppression Reduction [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating whether reducing transplant-immunosuppression around COVID-19 exposure provides protection for kidney and liver transplant recipients; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation
• Liver Transplantation

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Kidney Transplant Recipients, Liver Transplant Recipients | Phase 2 | Status: COMPLETED | Results posted: 2026-04-23